Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-040366
Filing Date
2025-08-14
Accepted
2025-08-14 16:02:18
Documents
63
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vyne-20250630.htm   iXBRL 10-Q 929624
2 EX-31.1 vyne-20250630xexx311.htm EX-31.1 9462
3 EX-31.2 vyne-20250630xexx312.htm EX-31.2 9456
4 EX-32.1 vyne-20250630xexx321.htm EX-32.1 5438
5 EX-32.2 vyne-20250630xexx322.htm EX-32.2 5447
  Complete submission text file 0001628280-25-040366.txt   5041742

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vyne-20250630.xsd EX-101.SCH 34431
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vyne-20250630_cal.xml EX-101.CAL 52476
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vyne-20250630_def.xml EX-101.DEF 143595
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vyne-20250630_lab.xml EX-101.LAB 483699
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vyne-20250630_pre.xml EX-101.PRE 325158
65 EXTRACTED XBRL INSTANCE DOCUMENT vyne-20250630_htm.xml XML 546837
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38356 | Film No.: 251218517
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)